



Article Cardiac Rupture—The Most Serious Complication of Takotsubo Syndrome: A Series of Five Cases and a Systematic Review

Małgorzata Zalewska-Adamiec^{1,*}, Hanna Bachórzewska-Gajewska^{1,2} and Sławomir Dobrzycki¹

- ¹ Department of Invasive Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; hgajewska@op.pl (H.B.-G.); kki@umb.edu.pl (S.D.)
- ² Department of Clinical Medicine, Medical University of Bialystok, 15-295 Bialystok, Poland
 - Correspondence: mzalewska5@wp.pl; Tel.: +48-(85)-8318496

Abstract: Background: The most serious complication of the acute Takotsubo phase is a myocardial perforation, which is rare, but it usually results in the death of the patient. Methods: In the years 2008-2020, 265 patients were added to the Podlasie Takotsubo Registry. Cardiac rupture was observed in five patients (1.89%), referred to as the Takotsubo syndrome with complications of cardiac rupture (TS+CR) group. The control group consisted of 50 consecutive patients with uncomplicated TS. The diagnosis of TS was based on the Mayo Clinic Criteria. Results: Cardiac rupture was observed in women with TS aged 74–88 years. Patients with TS and CR were older (82.20 vs. 64.84; p = 0.011), than the control group, and had higher troponin, creatine kinase, aspartate aminotransferase, and blood glucose levels (168.40 vs. 120.67; p = 0.010). The TS+CR group demonstrated a higher heart rate (95.75 vs. 68.38; *p* < 0.0001) and the Global Registry of Acute Coronary Events (GRACE) scores (186.20 vs. 121.24; p < 0.0001) than the control group. In patients with CR, ST segment elevation was recorded significantly more often in the III, V4, V5 and V6 leads. Left ventricular free wall rupture was noted in four patients, and in one case, rupture of the ventricular septum. In a multivariate logistic regression, the factors that increase the risk of CR in TS were high GRACE scores, and the presence of ST segment elevation in lead III. Conclusions: Cardiac rupture in TS is rare but is the most severe mechanical complication and is associated with a very high risk of death. The main risk factors for left ventricular perforation are female gender, older age, a higher concentration of cardiac enzymes, higher GRACE scores, and ST elevations shown using electrocardiogram (ECG).

Keywords: Takotsubo syndrome; cardiac rupture; cardiac perforation; acute coronary syndrome; cardiac tamponade

1. Introduction

Takotsubo syndrome (TS), first described in Japan around 30 years ago by Sato et al. [1], is a stress-induced transient impairment of left ventricular contractility with a concomitant increase in the level of cardiac enzymes and ischemic changes in electrocardiograms and with no significant atherosclerotic lesions in the coronary arteries. The clinical manifestation of TS is similar to that of an acute coronary syndrome (ACS). Its prognosis is usually benign, and the contractility disorders disappear within a few weeks to several months after the event. However, in the acute state, approximately 20% of patients have serious complications. The most frequently occurring complication is acute heart failure manifested by cardiogenic shock or pulmonary oedema. Cardiac rhythm and conduction disorders, including sudden cardiac arrest, are also frequently recorded. However, the most serious complication of the acute Takotsubo phase is a myocardial perforation, which is rare, but it usually results in the death of the patient [2–5].

The aim of this study was to identify the risk factors of cardiac rupture (CR) in Takotsubo syndrome. A systematic review of previously reported cases of CR in Takotsubo syndrome was also performed.



Citation: Zalewska-Adamiec, M.; Bachórzewska-Gajewska, H.; Dobrzycki, S. Cardiac Rupture—The Most Serious Complication of Takotsubo Syndrome: A Series of Five Cases and a Systematic Review. J. Clin. Med. 2021, 10, 1066. https:// doi.org/10.3390/jcm10051066

Academic Editor: Nicola Cosentino

Received: 27 January 2021 Accepted: 1 March 2021 Published: 4 March 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

2. Materials and Methods

2.1. Study Population

In the years 2008–2020, 265 patients were added to the Podlasie Takotsubo Registry. Cardiac rupture was observed in five patients (1.89%), referred to as the Takotsubo syndrome with complications of cardiac rupture (TS+CR) group. The control group consisted of 50 consecutive patients with uncomplicated Takotsubo syndrome, hospitalized at the authors' clinic.

In the analyzed patients, Takotsubo syndrome was diagnosed on the basis of the Mayo Clinic criteria [6], in force during their hospitalization. Cardiac rupture was diagnosed in imaging tests (i.e., echocardiography and ventriculography).

2.2. Systematic Review

For a systematic review, all Takotsubo syndrome cardiac rupture cases were searched in PubMed; 35 cases were found published between 2004 and 2020. The compilation took into account the age, sex, place of left ventricular perforation, and the patient's survival/death. The treatment was taken into account in the surviving patients.

2.3. Statistical Analysis

Both the test and control group data were statistically analyzed. We compared the quantitative variables using the Student's *t*-test and the Mann–Whitney *U*-test and compared the qualitative data using the chi-square and Fisher tests. Multivariate analysis was performed using logistic regression. A *p*-value of less than 0.05 was considered statistically significant. The analysis was performed using STATISTICA software, version 13.3 (StatSoft Poland, Cracow, Poland).

3. Results

3.1. General Characteristics

Cardiac rupture in Takotsubo syndrome was observed in women in the 74–88-year age group (average = 82.2 years). The Takotsubo syndrome patients with complications of CR (the TS+CR group) were older than the patients in the control group. In all five women in the TS+CR group, the main symptom of Takotsubo syndrome was retrosternal pain. Laboratory tests performed on admission in the TS+CR group showed higher values of troponin and creatine kinase than that of the control group; however, the differences were not statistically significant. The values obtained for glycemia were significantly higher for the TS+CR group than that of the control group (Table 1). The values obtained for glycated hemoglobin (HbA_{1C}) in the TS+CR group were normal (5.1–5.6%).

Patients in the TS+CR group demonstrated a significantly higher heart rate than that of the control group. In addition, the scores on the Global Registry of Acute Coronary Events (GRACE) scale were significantly higher for the TS+CR group than for the control group (Table 1).

In all five patients of the TS+CR group, the Takotsubo apical variant was diagnosed, including two patients with left ventricular middle segment involvement. In the control group, the apical variant was found in 49 patients (98%), including 15 with middle segment involvement. The focal-type TS was found in one patient.

| Clinical and demographic characteristics: Age (years) 82.20 ± 5.67 64.84 ± 14.51 0.011 Body mass index (BM) (kg/m ²) 24.02 ± 2.83 26.23 ± 5.27 0.415 Trigger factor: 0.00 $12 (24)$ 0.215 Emotional (%) $3 (60)$ $17 (34)$ 0.249 0.233 History of hypertension (%) $4 (80)$ $30 (60)$ 0.330 Hypertijdemia (%) $2 (40)$ $22 (46)$ 0.212 Diabetes mellitus (%) $0 (0)$ $14 (28)$ 0.172 Diabetes mellitus (%) $0 (0)$ $7 (14)$ 0.777 Snoking (%) $0 (0)$ $7 (14)$ 0.777 Character (%) $10 (0)$ $7 (14)$ 0.777 Diabetes mellitus (%) $0 (0)$ $7 (14)$ 0.777 Dianositi (mody disorder (%) $3 (60)$ $12 (24)$ 0.084 COPD (%) $0 (0)$ $6 (12) (24)$ 0.084 COPD (%) $0 (0)$ $6 (10) (20)$ 0.00 <td< th=""><th></th><th>TS+CR Group $n = 5$</th><th>TS Control Group $n = 50$</th><th><i>p</i>-Value</th></td<> | | TS+CR Group $n = 5$ | TS Control Group $n = 50$ | <i>p</i> -Value |
|---|--|------------------------------------|--------------------------------|-----------------|
| Age (years) 82.20 ± 5.67 64.84 ± 14.51 0.011 Body mass index (BM) (kg/m ²) $24.02 + 5.27$ 0.415 Trigger factor: - - Physical (%) $0.(0)$ $12.(24)$ 0.215 Emotional (%) $3.(60)$ $17.(34)$ 0.249 Absent/unknown (%) $2.(40)$ $21.(42)$ 0.930 History of hypertension (%) $4.(80)$ $30.(60)$ 0.380 Hyperipidemia (%) $2.(40)$ $21.(42)$ 0.930 Hyperipidemia (%) $2.(40)$ $21.(42)$ 0.330 Hyperipidemia (%) $0.(0)$ $14.(28)$ 0.171 Family history of cronary artery disease (%) $0.(0)$ $14.(28)$ 0.171 Chronic kidney disease (%) $0.(0)$ $14.(28)$ 0.171 Chronic kidney disease (%) $0.(0)$ $14.(28)$ 0.171 Chronic kidney disease (%) $0.(0)$ 12.20 0.0001 Diagnostic tests (chocardiography, coronargarghy, and ECC): $0.016.000$ $0.000.0000$ 0.1829 | Clinical and demographic characteristics: | | | |
| Fermine wave (%) 5 (100) 44 (62) 0.511 Body mass index (BMD) (kg/m ²) 24.02 ± 2.83 26.23 ± 5.27 0.415 Trigger factor: 12.02 0.213 Emotional (%) 0 (0) 12 (24) 0.239 Absent/unknown (%) 2 (40) 21 (42) 0.931 History of hypertension (%) 4 (80) 30 (60) 0.380 Hyperhylidemia (%) 2 (40) 23 (46) 0.797 Smoding (%) 0 (0) 14 (28) 0.171 Family history of coronary artery disease (%) 0 (0) 7 (44) 0.474 Thyproid disorders (%) 0 (0) 7 (44) 0.171 Chronic Marperssinn (%) 1 (20) 5 (100) 0.412 CHA2DS2-VASC scale (points) 4 600 12 (24) 0.491 CHA2DS2-VASC scale (points) 4 400 (0000) 3.00 (2000) 0.300 (2200) Diagnostic tests (chocardiagraphy, and ECG): 25 (50) 0.202 0.202 ECG-FF segment devation (%) 5 (100) 23 (45) 0.444 | Age (vears) | 82.20 ± 5.67 | 64.84 ± 14.51 | 0.011 |
| Body mass index (BMI) (kg/m ²) 24.02 ± 2.23 26.23 ± 5.27 0.415 Trigger factor: Physical (%) 0.00 12.(24) 0.215 Emotional (%) 3.(60) 17.(34) 0.229 Absent/unknovn (%) 2.(40) 23.(40) 0.30 Hyperlipidenia (%) 2.(40) 23.(40) 0.91 Smoothing (%) 0.00 14.(28) 0.171 Dabeter mellitus (%) 0.00 13.(20) 0.192 Dabeter mellitus (%) 0.00 14.(28) 0.171 Anxiety/depression (%) 1.(20) 5.(10) 0.414 Thryoid disorders (%) 0.00 14.(28) 0.172 Chronic kidney disease (%) 0.00 6.(12) 0.414 Chronic kidney disease (%) 0.00 6.(12) 0.414 Chronic kidney disease (%) 1.(20) 25.(50) 0.202 Normal coronary arteris (%) 1.(20) 25.(50) 0.202 Normal coronary arteris (%) 5.(100) 33.(66) 0.116 | Female sex (%) | 5 (100) | 46 (92) | 0.511 |
| Trigger factor: Physical (%) 0 | Body mass index (BMI) (kg/m^2) | 24.02 ± 2.83 | 26.23 ± 5.27 | 0.415 |
| Physical (%) 0 (0) 12 (24) 0.215 Enotional (%) 3 (60) 17 (34) 0.249 Absent/unknown (%) 2 (40) 21 (42) 0.330 History of hypertension (%) 4 (40) 30 (60) 0.380 Hypertipdemia (%) 0 (0) 14 (28) 0.171 Smoking (%) 0 (0) 13 (26) 0.192 Diabetes mellitus (%) 0 (0) 7 (14) 0.371 Anxiety (Aperasion (%) 1 (20) 5 (10) 0.44 Chronic (kindwy disease (%) 0 (0) 14 (28) 0.171 Chronic (kindwy disease (%) 3 (60) 12 (24) 0.084 COPP (%) 0 (0) 6 (12) 0.442 CHADDS2-VASE scale (points) 400 (0.000) 3.00 (2.000) 0.308 Diagnostic tests (echocardiography, coronarography, and ECC): Eff ventricular ejection fraction on admission (%) 3.860 \pm 7.89 3.944 \pm 10.52 0.783 Normal coronary atteris (%) 1 (20) 25 (50) 0.202 Non-significant stenses (%) 4 (80) 25 (50) | Trigger factor: | | | |
| Emotional (%) $3 (60)$ $7 (24)$ 0.239 Absent/unknown (%) $2 (40)$ $21 (42)$ 0.991 History of hypertension (%) $2 (40)$ $23 (46)$ 0.380 Hyperfipidemia (%) $0 (0)$ $14 (28)$ 0.171 Family history of coronary artery disease (%) $0 (0)$ $14 (28)$ 0.171 Daibebes melitus (%) $0 (0)$ $7 (14)$ 0.371 Anxiety / depression (%) $1 (20)$ $5 (10)$ 0.494 Anxiety / depression (%) $0 (0)$ $14 (28)$ 0.171 Chronic kidney discase (%) $3 (60)$ $12 (24)$ 0.084 COPD (%) $0 (0)$ $6 (12)$ 0.412 CHA2DS2-WASe scale (points) $4.00 ((0.00)$ $3.00 (2.00)$ 0.388 GRACE scale (points) 1620 ± 2.262 12124 ± 34.57 0.0001 Diagnostic tests (echocardiography, coronarography, and ECG): 0.00 $25 (50)$ 0.202 Non-significant stenoses (%) $4 (80)$ $25 (50)$ 0.202 Non-significant stenoses (%) $4 (20)$ $33 (66)$ 0.116 QTc on admission (%) 36.60 ± 7.89 39.94 ± 10.52 0.783 Normal coronary arteries (%) $5 (100)$ $33 (60)$ 0.202 ECG-ST segment elevation (%) $525.00 (157.00)$ $508.00 (37.00)$ 0.229 Laboratory parameters: $1200 \pm 20.80 (67.00)$ 0.229 Laboratory parameters: $1260 \pm 0.237 \pm 14.85$ 74.69 ± 22.24 0.233 GRace scale (%) $525.00 (157.00)$ $930.00 (30.00)$ 0.229 <td>Physical (%)</td> <td>0 (0)</td> <td>12 (24)</td> <td>0.215</td> | Physical (%) | 0 (0) | 12 (24) | 0.215 |
| Absent/unknown (%) 2 (40) 21 (42) 0.931 History of hypertension (%)4 (80)30 (60)0.380Hypertipidemia (%)2 (40)23 (46) 0.797 Smoking (%)0 (0)14 (28)0.171Family history of coronary artery disease (%)0 (0)14 (28)0.192Diabetes mellitus (%)0 (0)14 (28)0.494Thyroid disorders (%)0 (0)14 (28)0.494Thyroid disorders (%)0 (0)14 (28)0.171Chronic kidney disease (%)3 (60)12 (24)0.084COPD (%)0 (0)6 (12)0.412CH 42DS-VASc scale (points)400 (0.000)3.00 (2.000)0.138GRACE scale (points)186.20 ± 22.62121.24 ± 34.570.0001Diagnostic tests (chocardiography, coronarography, and ECG):25 (50)0.202Normal coronary arteris (%)1 (20)25 (50)0.202Normal coronary arteris (%)1 (20)25 (50)0.202Normal coronary arteris (%)5 (100)33 (66)0.116QT cor andmission (ms)48.85 b ± 52.22475.44 ± 38.980.747QT act a few days (ms)525.00 (157.000)508.00 (37.00)0.429Hemoglobin (mg/d1)12.62 ± 0.9213.45 ± 1.730.295Erythrocytes (×106/µL)42.88 (0.451)4.44 (0.591)0.151Hemoglobin (mg/d1)12.62 ± 0.9213.45 ± 1.730.295Creating (ms)53.50 ((157.00))9.552 ± 0.02130.0155Creating (ms)16.0 | Emotional (%) | 3 (60) | 17 (34) | 0.249 |
| History of hypertension (%) 4 (80) 30 (60) 0.380 Hyperlipidemia (%) 2 (40) 23 (46) 0.797 Smoking (%) 0 (0) 14 (28) 0.171 Pamily history of coronary artery disease (%) 0 (0) 7 (14) 0.371 Anxiety depression (%) 1 (20) 5 (10) 0.494 Thypoid disorders (%) 0 (0) 14 (28) 0.171 Chronic kidney disease (%) 3 (60) 12 (24) 0.084 CCPD (%) 0 (0) 6 (12) 0.412 CHA2DS2-VASe scale (points) 4.00 ((0.00) 3.00 (2.00) 0.38 GRACE scale (points) 1 (20) 25 (50) 0.202 Normal coronary arteries (%) 1 (20) 25 (50) 0.202 Normal coronary arteries (%) 4 (80) 25 (50) 0.202 Normal coronary arteries (%) 4 (80) 25 (50) 0.202 Normal coronary arteries (%) 5 (100) 33 (66) 0.16 QTc on admission (%) 4 (80) 25 (45) 0.21 Left ventricular ejeckion (%) | Absent/unknown (%) | 2 (40) | 21 (42) | 0.931 |
| Hyperlip/denia (%) 2 (40) 23 (46) 0.777 Smoking (%) 0 (0) 14 (28) 0.171 Family history of coronary artery disease (%) 0 (0) 7 (14) 0.371 Diabetes mellitus (%) 0 (0) 7 (14) 0.371 Anxiety (depression (%) 1 (20) 5 (10) 0.494 Thyroid disorders (%) 0 (0) 14 (28) 0.071 Chronic (kidney disease (%) 3 (60) 12 (24) 0.084 COPD (%) 0 (0) 6 (12) 0.441 CH 2025-2VASc scale (points) 400 (0.000) 3.00 ((2.000) 0.138 GRACE scale (points) 186.20 ± 2.262 121.24 ± 34.57 0.0001 Diagnostic tests (chocardiography, aromarography, and ECG): 25 (50) 0.202 Normal coronary arteries (%) 1 (20) 25 (50) 0.202 Normal coronary arteries (%) 1 (20) 25 (50) 0.202 Normal coronary arteries (%) 1 (20) 25 (50) 0.202 Red-Graphy, and ECG): 525.00 (157.000) 35 (66) 0.116 QTc attra few days (ms) 525.00 (157.0 | History of hypertension (%) | 4 (80) | 30 (60) | 0.380 |
| Smoking (%) 0 0 14 (28) 0.171 Family history of coronary artery disease (%) 0 (0) 13 (26) 0.192 Diabetes mellitus (%) 0 (0) 7 (14) 0.371 Anxiety/depression (%) 1 (20) 5 (10) 0.494 Thyroid disorders (%) 0 (0) 14 (28) 0.171 Chronic kidney disease (%) 3 (60) 12 (24) 0.084 COPD (%) 0 (0) 6 (12) 0.442 CHA2DS2-VAS: cale (points) 4.00 (0.00) 3.01 (2.00) 0.138 GRACE scale (points) 186.20 ± 22.62 12.12 ± ± ± 4.57 0.0001 Diagnostic tests (echocardiography, coronarography, and ECC): 12.02 2.5 (50) 0.202 Normailicant stenoses (%) 4 (80) 25 (50) 0.202 10.033 66.0 0.116 QTe and admission (ms) 468.50 5.25.00 (157.00) 33.60 ± 7.89 3.94 ± 10.52 0.783 Normaigrificant stenoses (%) 4 (80.5) 5.12.01 4.808 0.747 QTe ather a few days (ms) 525.00 ((157 | Hyperlipidemia (%) | 2(40) | 23 (46) | 0.797 |
| Family history of coronary artery disease (%) 0 (0) 13 (26) 0.192 Diabetes mellitus (%) 0 (0) 7 (14) 0.371 Anxiety/depression (%) 1 (20) 5 (10) 0.494 Thyroid disorders (%) 0 (0) 14 (28) 0.171 Chronic kichney disease (%) 3 (60) 12 (24) 0.001 Chronic kichney disease (%) 3 (60) 12 (24) 0.001 Chronic kichney disease (%) 0 (0) 6 (12) 0.412 CHA2DS2-VASc scale (points) 186 (24) ± 2.62 121 24 ± 34.57 0.0001 Diagnostic tests (echocardiography, coronarography, and ECG): 12 (20) 25 (50) 0.202 Normal coronary arteries (%) 4 (80) 25 (50) 0.202 Normal coronary arteries (%) 4 (80) 25 (50) 0.202 Normal coronary arteries (%) 4 (80) 25 (50) 0.202 Normal coronary arteries (%) 4 (80) 25 (50) 0.202 Left ventricular elevation (%) 5 (100) 38 (66) 0.116 0.774 QTc anter a few days (ms) 525.00 (157.00) 80.80 (17.00) | Smoking (%) | 0(0) | 14(28) | 0 171 |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Family history of coronary artery disease (%) | 0(0) | 13 (26) | 0.192 |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | Diabetes mellitus (%) | 0 (0) | 7(14) | 0.371 |
| $\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$ | Anyiety/depression (%) | 1(20) | 5(10) | 0.371 |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Thuraid disorders (%) | 1(20) | 14(28) | 0.474 |
| Linkink Uncess (n_{0}) 5 (00) 12 (24) 0.004 COPD (γ_{0}) 0 (0) 6 (12) 0.412 CHA2DS2-VASc scale (points) 4.00 ((0.00) 3.00 ((2.00)) 0.138 GRACE scale (points) 186.20 ± 22.62 121.24 ± 34.57 0.0001 Diagnostic tests (echocardiography, coronarography, and ECG): 0.783 0.783 Normal coronary arteries (γ_{0}) 1 (20) 25 (50) 0.202 Normal coronary arteries (γ_{0}) 4 (80) 25 (50) 0.202 ECG—ST segment elevation (γ_{0}) 5 (100) 33 (66) 0.116 QTc after a few days (ms) 525.00 (157.00) 508.00 ((37.00) 0.429 Laboratory parameters: | Chronic kidney disease (%) | 0 (0) 3 (60) | 14(20) 12(24) | 0.171 |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | COPD(9/2) | 3 (00) | 12(24) | 0.004 |
| ChrADb2-VASe scale (points) 4.00 ((0.00) 3.00 ((2.00) 0.138 GRACE scale (points) 186.20 ± 22.62 121.24 ± 34.57 0.0001 Diagnostic tests (echocardiography, coronarography, and ECG): 120 25 (50) 0.202 Normal coronary arteries (%) 1 (20) 25 (50) 0.202 Normal coronary arteries (%) 4 (80) 25 (50) 0.202 ECG—ST segment elevation (%) 5 (100) 33 (66) 0.116 QTc after a few days (ms) 525.00 (157.00) 508.00 ((37.00) 0.429 Laboratory parameters: | CULA 2DC2 MAGa angle (a ginta) | | 6(12) | 0.412 |
| Display Display <thdisplay< th=""> <t< td=""><td>CHA2D52-VASC scale (points) CRACE scale (points)</td><td>4.00((0.00)) 186.20 \pm 22.62</td><td>3.00((2.00)) 121 24 + 34 57</td><td>0.138</td></t<></thdisplay<> | CHA2D52-VASC scale (points) CRACE scale (points) | 4.00((0.00)) 186.20 \pm 22.62 | 3.00((2.00)) 121 24 + 34 57 | 0.138 |
| Displays | Diagnostic tests (echocardiography, coronarography, and ECC): | 100.20 ± 22.02 | 121.27 ± 34.37 | 0.0001 |
| Deriverint ventrular ejection in factori on factorison (%) 36.00 ± 7.87 37.94 ± 10.52 0.783 Normal coronary arteries (%)4 (80)25 (50)0.202ECG—ST segment elevation (%)5 (100)33 (66)0.116QTc on admission (ms)468.50 ± 52.22 475.44 ± 38.98 0.747QTc after a few days (ms)525.00 ((157.00))508.00 ((37.00))0.429Laboratory parameters: | Last vontrigular election fraction on admission (0^{\prime}) | 28 60 1 7 80 | 20.04 - 10.52 | 0 792 |
| Normal coronary arteries (%)1 (20)25 (50)0.202Non-significant stenoses (%)4 (80)25 (50)0.202ECG—ST segment elevation (%)5 (100)33 (66)0.116QTc on admission (ms)468.50 ± 52.22475.44 ± 38.980.747QTc atler a few days (ms)525.00 (157.00)508.00 ((37.00))0.429Laboratory parameters:12.62 ± 0.9213.45 ± 1.730.295Erythrocytes (× 106 / µL)4.28 ((0.45))4.44 ((0.59))0.151Hemoglobin (mg/dL)11.66 ± 2.809.52 ± 3.690.213Clucose on admission (mg/dL)10.600 ((50.00))112.00 ((36.00))0.015Creatinine (mg/dL)0.90 ((0.18))0.75 ((0.26))0.395eGFR MDRD (mL/min/1.72 m²)62.37 ± 14.8574.69 ± 22.240.233CK (U/L)275.00 ((574.50)199.50 ((203.00))0.126Troponin (significant increase) (%)5 (100)48 (96)0.648Troponin (significant increase) (%)5 (100)48 (96)0.276AbAT (mg/dL)23.00 ((69.00))21.00 ((13.00))0.776Total cholesterol (mg/dL)171.50 ± 25.49186.06 ± 42.610.506LDL (mg/dL)97.45 ± 37.67117.62 ± 38.820.323HDL (mg/dL)97.465 (711.7)464.00 (26.71)0.058Clinical course and mortality:123.00 ± 36.51123.28 ± 23.940.981HR on admission95.75 ± 22.4668.38 ± 11.42<0.0001 | Left ventricular ejection fraction on admission (%) | 38.00 ± 7.89 | 39.94 ± 10.52 | 0.783 |
| Non-significant stenoses (%)4 (80)25 (50)0.202ECG—ST segment elevation (%)5 (100)33 (66)0.116QTc on admission (ms)468.50 \pm 52.22475.44 \pm 38.980.747QTc after a few days (ms)525.00 (157.00)508.00 ((37.00)0.429Laboratory parameters:Hemoglobin (mg/dL)12.62 \pm 0.9213.45 \pm 1.730.295Erythrocytes (x106/µL)4.28 ((0.45))4.44 ((0.59))0.151Hematocrift (%)36.30 ((2.30))39.40 ((56.00))0.229Leukocytes (x103/µL)11.66 \pm 2.809.52 \pm 3.690.213Glucose on admission (mg/dL)0.90 ((0.18))0.75 ((0.26))0.395eGFR MDRD (mL/min/1.72 m²)62.37 \pm 14.8574.69 \pm 22.240.233CK (U/L)275.00 ((574.50))199.50 ((203.00))0.126Troponin (significant increase) (%)5 (100)48 (96)0.648Troponin-mean concentration (ng/mL)2.59 ((7.03)2.13 ((3.70))0.776AspAT (mg/dL)23.00 ((82.50))32.00 ((27.00))0.276AlaT (mg/dL)17.150 \pm 25.49186.06 \pm 42.610.506LDL (mg/dL)97.45 \pm 37.67117.62 \pm 38.820.323HDL (mg/dL)13.300 ((18.75))79.00 ((58.00))0.056CRP (mg/L)13.70 ((40.20))20.35 ((27.30))0.933BNP (pg/mL)97.465 (711.7)464.00 (260.71)0.058UDL (mg/dL)5.10041 (82)0.299Dyspnea (%)0 (0)6 (12)0.411Killip class II | Normal coronary arteries (%) | 1 (20) | 25 (50) | 0.202 |
| ECG—SI segment elevation (%) 5 (100) 33 (66) 0.116 QTc on admission (ms) 468.50 \pm 52.22 475.44 \pm 38.98 0.747 QTc after a few days (ms) 525.00 (157.00) 508.00 ((37.00) 0.429 Laboratory parameters: | Non-significant stenoses (%) | 4 (80) | 25 (50) | 0.202 |
| Q1c on admission (ms) 468.502 475.44 ± 38.98 0.747 Q1c after a few days (ms) 525.00 (157.00)) 508.00 ((37.00)) 0.429 Laboratory parameters: 12.62 ± 0.92 13.45 ± 1.73 0.295 Erythrocytes (× 106/µL) 4.28 (0.45)) 4.44 (0.59)) 0.151 Hematocrit (%) 36.30 ((2.30)) 39.40 ((5.60)) 0.229 Leukocytes (× 103/µL) 11.66 ± 2.80 9.52 ± 3.69 0.213 Glucose on admission (mg/dL) 0.90 ((0.18)) 0.75 ((0.26)) 0.395 eGFR MDRD (mL/min/1.72 m²) 62.37 ± 14.85 74.69 ± 22.24 0.233 CK (IU/L) 275.00 ((0574.50)) 199.50 ((203.00)) 0.126 Troponin (significant increase) (%) 5 (100) 48 (%6) 0.648 Troponin-mean concentration (ng/mL) 2.59 ((7.03)) 2.13 ((3.70)) 0.726 AspAT (mg/dL) 23.00 ((682.50)) 32.00 ((27.00)) 0.276 AspAT (mg/dL) 23.00 ((682.50)) 32.00 ((27.00)) 0.276 AspAT (mg/dL) 53.50 ((182.50)) 32.00 ((27.00)) 0.276 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 61.55 ± 11.09 50.66 ± 14.261 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 BPP on admission 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 0.0001 Retrosternal chest pain (%) 5 (100) $41(82)$ 0.299 <td< td=""><td>ECG—SI segment elevation (%)</td><td>5 (100)</td><td>33 (66)</td><td>0.116</td></td<> | ECG—SI segment elevation (%) | 5 (100) | 33 (66) | 0.116 |
| Q1c after a few days (ms) $525.00 ((157.00))$ $508.00 ((37.00))$ 0.429 Laboratory parameters:Hemoglobin (mg/dL) 12.62 ± 0.92 13.45 ± 1.73 0.295 Erythrocytes (×106/µL) $4.28 ((0.45))$ $4.44 ((0.59))$ 0.151 Hematocrii (%) $36.30 ((2.30)$ $39.40 ((5.60))$ 0.229 Leukocytes (×103/µL) 11.66 ± 2.80 9.52 ± 3.69 0.213 Glucose on admission (mg/dL) $0.90 ((0.18))$ $0.75 ((0.26))$ 0.395 eGFR MDRD (mL/min/1.72 m²) 62.37 ± 14.85 74.69 ± 22.24 0.233 CK (IU/L) $275.00 ((574.50))$ $199.50 ((203.00))$ 0.126 Troponin (significant increase) (%) $5 (100)$ $48 (96)$ 0.648 Troponin main concentration (ng/mL) $2.59 ((7.03))$ $2.13 ((3.70))$ 0.276 AlAT (mg/dL) $23.00 ((69.00))$ $21.00 ((13.00))$ 0.775 Total cholesterol (mg/dL) 171.50 ± 25.49 180.60 ± 42.61 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) $13.70 ((40.20))$ $20.35 ((27.30))$ 0.933 BNP (pg/mL) $97.465 (711.7)$ $464.00 (260.71)$ 0.058 Clinical course and mortality: 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) $5 (100)$ $41 (82)$ 0.299 Dyspnea (%) $0 (0)$ $6 (12)$ 0.411 Killip class III/IV on admission (%) $1 (20)$ <td>QIc on admission (ms)</td> <td>468.50 ± 52.22</td> <td>475.44 ± 38.98</td> <td>0.747</td> | QIc on admission (ms) | 468.50 ± 52.22 | 475.44 ± 38.98 | 0.747 |
| Laboratory parameters:Hemoglobin (mg/dL) 12.62 ± 0.92 13.45 ± 1.73 0.295 Erythrocytes (×106/µL) 4.28 ((0.45)) 4.44 ((0.59)) 0.151 Hematocrit (%) 36.30 ((2.30)) 39.40 ((5.60)) 0.229 Leukocytes (×103/µL) 11.66 ± 2.80 9.52 ± 3.69 0.213 Glucose on admission (mg/dL) 160.00 ((50.00)) 112.00 ((36.00)) 0.015 Creatinine (mg/dL) 0.90 ((0.18)) 0.75 ((0.26)) 0.395 eGFR MDRD (mL/min/1.72 m²) 62.37 ± 14.85 74.69 ± 22.24 0.233 C K (U/L) 275.00 ((574.50)) 199.50 ((203.00)) 0.126 Troponin (significant increase) (%) 5 (100) 48 (96) 0.648 Troponin (significant increase) (%) 5 (100) 48 (96) 0.648 Troponin (significant increase) (%) 5 (100) 48 (96) 0.648 Troponin-mean concentration (ng/mL) 2.59 ((7.03)) 2.13 ((3.70)) 0.276 AlAT (mg/dL) 33.50 ((82.50)) 32.00 ((27.00)) 0.276 AlAT (mg/dL) 97.45 ± 37.67 117.62 ± 38.2 0.323 HDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.2 0.323 HDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 BNP (pg/nL) 97.465 (711.7) 464.00 (260.71) 0.056 C (Inical course and mortality: 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) <t< td=""><td>QIc after a few days (ms)</td><td>525.00 ((157.00))</td><td>508.00 ((37.00))</td><td>0.429</td></t<> | QIc after a few days (ms) | 525.00 ((157.00)) | 508.00 ((37.00)) | 0.429 |
| Hemoglobin (mg/dL) 12.62 ± 0.92 13.43 ± 1.73 0.295 Erythrocytes (×106/µL) $4.28 (0.45)$) $4.44 ((0.59)$) 0.151 Hematocrit (%) $36.30 ((2.30)$) $39.40 ((5.60)$) 0.229 Leukocytes (×103/µL) 11.66 ± 2.80 9.52 ± 3.69 0.213 Glucose on admission (mg/dL) $1000 ((0.18)$) $0.75 ((0.26)$) 0.395 eGFR MDRD (mL/min/1.72 m²) 62.37 ± 14.85 74.69 ± 22.24 0.233 CK (IU/L) $275.00 ((574.50)$) $199.50 ((203.00)$) 0.126 Troponin (significant increase) (%) $5 (100)$ $48 (96)$ 0.648 Troponin mean concentration (mg/mL) $2.59 ((7.03)$ $2.13 ((3.70))$ 0.726 AspAT (mg/dL) $53.50 ((82.50)$) $32.00 ((27.00))$ 0.276 AlAT (mg/dL) $23.00 ((69.00))$ $21.00 ((13.00))$ 0.775 Total cholesterol (mg/dL) 171.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 61.55 ± 11.09 50.66 ± 42.61 0.506 LDL (mg/dL) $53.00 ((18.75))$ $79.00 ((58.00))$ 0.056 CRP (mg/L) $13.70 ((40.20))$ $20.35 ((27.30))$ 0.933 BNP (pg/mL) $97.45 \pm 51.1.09$ 50.06 ± 18.08 0.219 Triglycerides (mg/dL) $51.30 ((40.20))$ $20.35 ((27.30))$ 0.933 BNP (pg/mL) 97.45 ± 51.109 50.06 ± 18.08 0.219 MDL (mg/dL) 61.55 ± 11.09 50.66 ± 18.08 0.219 Dyspnea (%) $0 (0)$ 41.82 0.299 Dyspnea (%) $0 (0)$ <td< td=""><td>Laboratory parameters:</td><td></td><td></td><td></td></td<> | Laboratory parameters: | | | |
| Erythrocytes (× 106/µL) $4.28 ((0.45))$ $4.44 ((0.59))$ 0.151 Hematocrit (%) $36.30 ((2.30))$ $39.40 ((5.60))$ 0.229 Leukocytes (× 103/µL) 11.66 ± 2.80 9.52 ± 3.69 0.213 Glucose on admission (mg/dL) $160.00 ((50.00))$ $112.00 ((36.00))$ 0.015 Creatinine (mg/dL) $0.90 ((0.18))$ $0.75 ((0.26))$ 0.395 eGFR MDRD (mL/min/1.72 m ²) 62.37 ± 14.85 74.69 ± 22.24 0.233 CK (IU/L) $275.00 ((574.50))$ $199.50 ((203.00))$ 0.126 Troponin (significant increase) (%) $5 (100)$ $48 (96)$ 0.648 Troponin-mean concentration (ng/mL) $2.59 ((7.03))$ $2.13 ((3.70))$ 0.726 AspAT (mg/dL) $53.50 ((82.50))$ $32.00 ((27.00))$ 0.776 AlAT (mg/dL) $23.00 ((69.00))$ $21.00 ((13.00))$ 0.775 Total cholesterol (mg/dL) 71.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 61.55 ± 11.09 50.06 ± 18.08 0.219 Triglycerides (mg/dL) $53.00 ((18.75))$ $79.00 ((58.00))$ 0.056 Clinical course and mortality: 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) $5 (100)$ $41 (82)$ 0.299 Dyspnea (%) $0 (0)$ $6 (12)$ 0.411 Killip class III/V on admission (%) $1 (20)$ $5 (10)$ 0.494 Pneumonia (%) $1 (20)$ $5 (10)$ 0.494 Pn | Hemoglobin (mg/dL) | 12.62 ± 0.92 | 13.45 ± 1.73 | 0.295 |
| Hematocrit (%) $39.30 ((2.30)$) $39.40 ((5.60)$) 0.229 Leukocytes (×103/µL) 11.66 ± 2.80 9.52 ± 3.69 0.213 Glucose on admission (mg/dL) $160.00 ((50.00)$) $112.00 ((36.00)$) 0.015 Creatinine (mg/dL) $0.90 ((0.18)$) $0.75 ((0.26)$) 0.395 eGFR MDRD (mL/min/1.72 m²) 62.37 ± 14.85 74.69 ± 22.24 0.233 CK (IU/L) $275.00 ((574.50)$) $199.50 ((203.00)$) 0.126 Troponin (significant increase) (%) $5 (100)$ $48 (96)$ 0.648 Troponin—mean concentration (ng/mL) $2.59 ((7.03)$) $2.13 ((3.70))$ 0.726 AspAT (mg/dL) $33.50 ((82.50)$) $32.00 ((27.00))$ 0.276 AlAT (mg/dL) $23.00 ((69.00)$) $21.00 ((13.00))$ 0.775 Total cholesterol (mg/dL) 171.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 61.55 ± 11.09 50.06 ± 18.08 0.219 Triglycerides (mg/dL) $31.30 ((18.75))$ $79.00 ((58.00))$ 0.056 CRP (mg/L) $31.30 (40.20)$ $20.35 ((27.30))$ 0.933 BNP (pg/mL) $974.65 (711.7)$ $464.00 (260.71)$ 0.058 Clinical course and mortality:Clinical course and mortality:Preumonia (%) $1(20)$ $5 (10)$ 0.494 Pneumonia (%) $1(20)$ $5 (10)$ 0.494 Pneumonia (%) $1(20)$ $5 (10)$ 0.799 Rhythm disturbances (%) </td <td>Erythrocytes (×106/µL)</td> <td>4.28 ((0.45))</td> <td>4.44 ((0.59))</td> <td>0.151</td> | Erythrocytes (×106/µL) | 4.28 ((0.45)) | 4.44 ((0.59)) | 0.151 |
| Leukocytes (x103/µL)11.66 ± 2.80 9.52 ± 3.69 0.213Glucose on admission (mg/dL)160.00 ((50.00))112.00 ((36.00))0.015Creatinine (mg/dL)0.90 ((0.18))0.75 ((0.26))0.395eGFR MDRD (mL/min/1.72 m²) 62.37 ± 14.85 74.69 ± 22.24 0.233CK (IU/L)275.00 ((574.50))199.50 ((203.00))0.126Troponin (significant increase) (%) 5 (100)48 (96)0.648Troponin –mean concentration (ng/mL) 2.59 ((7.03)) 2.13 ((3.70))0.726AspAT (mg/dL)53.50 ((82.50))32.00 ((27.00))0.276AlAT (mg/dL)23.00 ((69.00))21.00 ((13.00))0.775Total cholesterol (mg/dL)171.50 ± 25.49 186.06 ± 42.61 0.506LDL (mg/dL)61.55 ± 11.09 50.06 ± 18.08 0.219Triglycerides (mg/dL)53.00 ((18.75))79.00 ((58.00))0.056CRP (mg/L)13.70 ((40.20))20.35 ((27.30))0.933BNP (pg/mL)974.65 (711.7)464.00 (260.71)0.058Clinical course and mortality:5 (100)41 (82)0.299Dyspnea (%)0 (0)6 (12)0.411Killip class III/IV on admission (%)1 (20)5 (10)0.494Pneumonia (%)1 (20)5 (10)0.494Pneumonia (%)1 (20)13 (26)0.769Rhythm disturbances (%)0 (00)4 (8)0.511Hospial mortality (%)4 (80)4 (8)0.511 | Hematocrit (%) | 36.30 ((2.30)) | 39.40 ((5.60)) | 0.229 |
| Glucose on admission (mg/dL) 160.00 ((50.00)) 112.00 ((36.00)) 0.015 Creatinine (mg/dL) 0.90 ((0.18)) 0.75 ((0.26)) 0.395 eGFR MDRD (mL/min/1.72 m²) 62.37 ± 14.85 74.69 ± 22.24 0.233 CK (IU/L) 275.00 ((574.50)) 199.50 ((203.00)) 0.126 Troponin (significant increase) (%) 5 (100) 48 (96) 0.648 Troponin—mean concentration (ng/mL) 2.59 ((7.03)) 2.13 ((3.70)) 0.726 AspAT (mg/dL) 53.50 ((82.50)) 32.00 ((27.00)) 0.276 AlAT (mg/dL) 23.00 ((69.00)) 21.00 ((13.00)) 0.775 Total cholesterol (mg/dL) 171.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 61.55 ± 11.09 50.06 ± 18.08 0.219 Triglycerides (mg/dL) 13.70 ((40.20)) 20.35 ((27.30)) 0.933 BNP (pg/mL) 97.465 (711.7) 464.00 (260.71) 0.058 Clinical course and mortality:BPs on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) 5 (100) 41 (82) 0.299 Dyspnea (%) 0 (00) 6 (12) 0.411 Killip class III/IV on admission (%) 1 (20) 5 (100) 0.494 Pneumonia (%) 1 (20) 13 (26) 0.769 Rhythm disturbances (%) 0 (00) 4 (8) 0.511 | Leukocytes ($\times 103/\mu$ L) | 11.66 ± 2.80 | 9.52 ± 3.69 | 0.213 |
| Creatinine (mg/dL) 0.90 ((0.18)) 0.75 ((0.26)) 0.395 eGFR MDRD (mL/min/1.72 m²) 62.37 ± 14.85 74.69 ± 22.24 0.233 CK (IU/L) 275.00 ((574.50)) 199.50 ((203.00)) 0.126 Troponin (significant increase) (%) 5 (100) 48 (96) 0.648 Troponin—mean concentration (ng/mL) 2.59 ((7.03)) 2.13 ((3.70)) 0.726 AspAT (mg/dL) 53.50 ((82.50)) 32.00 ((27.00)) 0.276 AlAT (mg/dL) 23.00 ((69.00)) 21.00 ((13.00)) 0.775 Total cholesterol (mg/dL) 171.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 BNP (pg/mL) 53.00 ((18.75)) 79.00 ((58.00)) 0.056 CRP (mg/L) 13.70 ((40.20)) 20.35 ((27.30)) 0.933 BNP (pg/mL) 974.65 (711.7) 464.00 (260.71) 0.058 Clinical course and mortality: 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) 5 (100) 41 (82) 0.299 Dyspnea (%) 0 (0) 6 (12) 0.411 Killip class III/IV on admission (%) 1 (20) 5 (10) 0.494 Pneumonia (%) 1 (20) 5 (10) 0.494 Pneumonia (%) 1 (20) 4 (8) <td>Glucose on admission (mg/dL)</td> <td>160.00 ((50.00))</td> <td>112.00 ((36.00))</td> <td>0.015</td> | Glucose on admission (mg/dL) | 160.00 ((50.00)) | 112.00 ((36.00)) | 0.015 |
| eGFR MDRD (mL/min/1.72 m²) 62.37 ± 14.85 74.69 ± 22.24 0.233 CK (IU/L)275.00 ((574.50))199.50 ((203.00)) 0.126 Troponin (significant increase) (%) 5 (100) 48 (96) 0.648 Troponin-mean concentration (ng/mL) 2.59 ((7.03)) 2.13 ((3.70)) 0.726 AspAT (mg/dL) 53.50 ((82.50)) 32.00 ((27.00)) 0.276 AlAT (mg/dL) 23.00 ((69.00)) 21.00 ((13.00)) 0.775 Total cholesterol (mg/dL) 171.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 61.55 ± 11.09 50.06 ± 18.08 0.219 Triglycerides (mg/dL) 53.00 ((18.75)) 79.00 ((58.00)) 0.056 CRP (mg/L) 13.70 ((40.20)) 20.35 ((27.30)) 0.933 BNP (pg/mL) 974.65 (711.7) 464.00 (260.71) 0.058 Clinical course and mortality:LLilip class III/IV on admission (%) 1 (20) 4 (82) 0.299 Dyspnea (%) 0 (0) 6 (12) 0.411 Killip class III/IV on admission (%) 1 (20) 13 (26) 0.769 Rhythm disturbances (%) 0 (0) 4 (8) <0.0011 | Creatinine (mg/dL) | 0.90 ((0.18)) | 0.75 ((0.26)) | 0.395 |
| CK (IU/L)275.00 ((574.50))199.50 ((203.00))0.126Troponin (significant increase) (%)5 (100)48 (96)0.648Troponin—mean concentration (ng/mL)2.59 ((7.03))2.13 ((3.70))0.726AspAT (mg/dL)53.50 ((82.50))32.00 ((27.00))0.276AlAT (mg/dL)23.00 ((69.00))21.00 ((13.00))0.775Total cholesterol (mg/dL)171.50 \pm 25.49186.06 \pm 42.610.506LDL (mg/dL)97.45 \pm 37.67117.62 \pm 38.820.323HDL (mg/dL)61.55 \pm 11.0950.06 \pm 18.080.219Triglycerides (mg/dL)53.00 ((18.75))79.00 ((58.00))0.056CRP (mg/L)13.70 ((40.20))20.35 ((27.30))0.933BNP (pg/mL)974.65 (711.7)464.00 (260.71)0.058Clinical course and mortality:5 (100)41 (82)0.299Dyspnea (%)0 (0)6 (12)0.411Killip class III/IV on admission (%)1 (20)5 (10)0.494Pneumonia (%)1 (20)13 (26)0.769Rhythm disturbances (%)0 (0)4 (80)4 (80)<0.0001 | $eGFR MDRD (mL/min/1.72 m^2)$ | 62.37 ± 14.85 | 74.69 ± 22.24 | 0.233 |
| Troponin (significant increase) (%) $5 (100)$ $48 (96)$ 0.648 Troponin—mean concentration (ng/mL) $2.59 ((7.03))$ $2.13 ((3.70))$ 0.726 AspAT (mg/dL) $53.50 ((82.50))$ $32.00 ((27.00))$ 0.276 AlAT (mg/dL) $23.00 ((69.00))$ $21.00 ((13.00))$ 0.775 Total cholesterol (mg/dL) 171.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 61.55 ± 11.09 50.06 ± 18.08 0.219 Triglycerides (mg/dL) $53.00 ((18.75))$ $79.00 ((58.00))$ 0.056 CRP (mg/L) $13.70 ((40.20))$ $20.35 ((27.30))$ 0.933 BNP (pg/mL) $974.65 (711.7)$ $464.00 (260.71)$ 0.058 Clinical course and mortality:USING Clinical cour | CK (IU/L) | 275.00 ((574.50)) | 199.50 ((203.00)) | 0.126 |
| Troponin—mean concentration (ng/mL) $2.59 ((7.03))$ $2.13 ((3.70))$ 0.726 AspAT (mg/dL) $53.50 ((82.50))$ $32.00 ((27.00))$ 0.276 AlAT (mg/dL) $23.00 ((69.00))$ $21.00 ((13.00))$ 0.775 Total cholesterol (mg/dL) 171.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 61.55 ± 11.09 50.06 ± 18.08 0.219 Triglycerides (mg/dL) $53.00 ((18.75))$ $79.00 ((58.00))$ 0.056 CRP (mg/L) $13.70 ((40.20))$ $20.35 ((27.30))$ 0.933 BNP (pg/mL) $974.65 (711.7)$ $464.00 (260.71)$ 0.058 Clinical course and mortality:Event state of the st | Troponin (significant increase) (%) | 5 (100) | 48 (96) | 0.648 |
| AspAT (mg/dL) $53.50 ((82.50))$ $32.00 ((27.00))$ 0.276 AlAT (mg/dL) $23.00 ((69.00))$ $21.00 ((13.00))$ 0.775 Total cholesterol (mg/dL) 171.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 61.55 ± 11.09 50.06 ± 18.08 0.219 Triglycerides (mg/dL) $53.00 ((18.75))$ $79.00 ((58.00))$ 0.056 CRP (mg/L) $13.70 ((40.20))$ $20.35 ((27.30))$ 0.933 BNP (pg/mL) $974.65 (711.7)$ $464.00 (260.71)$ 0.058 Clinical course and mortality:Evolution of the state of the stat | Troponin—mean concentration (ng/mL) | 2.59 ((7.03)) | 2.13 ((3.70)) | 0.726 |
| AlAT (mg/dL)23.00 ((69.00))21.00 ((13.00))0.775Total cholesterol (mg/dL) 171.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 61.55 ± 11.09 50.06 ± 18.08 0.219 Triglycerides (mg/dL) 53.00 ((18.75)) 79.00 ((58.00)) 0.056 CRP (mg/L) 13.70 ((40.20)) 20.35 ((27.30)) 0.933 BNP (pg/mL) 974.65 (711.7) 464.00 (260.71) 0.058 Clinical course and mortality:Clinical course and mortality:Use of (12) 0.411 Killip class III/IV on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Killip class III/IV on admission (%) 1 (20) 5 (100) 0.411 Killip class III/IV on admission (%) 1 (20) 13 (26) 0.769 Rhythm disturbances (%) 0 (0) 4 (8) 0.511 Hospital mortality (%) 4 (80) 4 (8) <0.0001 | AspAT (mg/dL) | 53.50 ((82.50)) | 32.00 ((27.00)) | 0.276 |
| Total cholesterol (mg/dL) 171.50 ± 25.49 186.06 ± 42.61 0.506 LDL (mg/dL) 97.45 ± 37.67 117.62 ± 38.82 0.323 HDL (mg/dL) 61.55 ± 11.09 50.06 ± 18.08 0.219 Triglycerides (mg/dL) 53.00 ((18.75)) 79.00 ((58.00)) 0.056 CRP (mg/L) 13.70 ((40.20)) 20.35 ((27.30)) 0.933 BNP (pg/mL) 974.65 (711.7) 464.00 (260.71) 0.058 Clinical course and mortality:EVENTIANABPs on admission 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) 5 (100) 41 (82) 0.299 Dyspnea (%) 0 (0) 6 (12) 0.411 Killip class III/IV on admission (%) 1 (20) 5 (100) 0.494 Pneumonia (%) 1 (20) 13 (26) 0.769 Rhythm disturbances (%) 0 (0) 4 (8) <0.001 | AlAT (mg/dL) | 23.00 ((69.00)) | 21.00 ((13.00)) | 0.775 |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | Total cholesterol (mg/dL) | 171.50 ± 25.49 | 186.06 ± 42.61 | 0.506 |
| HDL (mg/dL) 61.55 ± 11.09 50.06 ± 18.08 0.219 Triglycerides (mg/dL) 53.00 ((18.75)) 79.00 ((58.00)) 0.056 CRP (mg/L) 13.70 ((40.20)) 20.35 ((27.30)) 0.933 BNP (pg/mL) 974.65 (711.7) 464.00 (260.71) 0.058 Clinical course and mortality:Clinical course and mortality:BPs on admission 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) 5 (100) 41 (82) 0.299 Dyspnea (%) 0 (0) 6 (12) 0.411 Killip class III/IV on admission (%) 1 (20) 5 (10) 0.494 Pneumonia (%) 1 (20) 13 (26) 0.769 Rhythm disturbances (%) 0 (0) 4 (8) 0.511 Hospital mortality (%) 4 (80) 4 (8) <0.0001 | LDL (mg/dL) | 97.45 ± 37.67 | 117.62 ± 38.82 | 0.323 |
| Triglycerides (mg/dL) $53.00 ((18.75))$ $79.00 ((58.00))$ 0.056 CRP (mg/L) $13.70 ((40.20))$ $20.35 ((27.30))$ 0.933 BNP (pg/mL) $974.65 (711.7)$ $464.00 (260.71)$ 0.058 Clinical course and mortality:BPs on admission 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) $5 (100)$ $41 (82)$ 0.299 Dyspnea (%) $0 (0)$ $6 (12)$ 0.411 Killip class III/IV on admission (%) $1 (20)$ $5 (100)$ 0.494 Pneumonia (%) $1 (20)$ $13 (26)$ 0.769 Rhythm disturbances (%) $0 (0)$ $4 (8)$ <0.0001 | HDL (mg/dL) | 61.55 ± 11.09 | 50.06 ± 18.08 | 0.219 |
| CRP (mg/L) $13.70 ((40.20))$ $20.35 ((27.30))$ 0.933 BNP (pg/mL) $974.65 (711.7)$ $464.00 (260.71)$ 0.058 Clinical course and mortality:BPs on admissionHR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) $5 (100)$ $41 (82)$ 0.299 Dyspnea (%) $0 (0)$ $6 (12)$ 0.411 Killip class III/IV on admission (%) $1 (20)$ $5 (100)$ 0.494 Pneumonia (%) $1 (20)$ $5 (10)$ 0.494 Hospital mortality (%) $4 (80)$ $4 (8)$ <0.0001 | Triglycerides (mg/dL) | 53.00 ((18.75)) | 79.00 ((58.00)) | 0.056 |
| BNP (pg/mL) $974.65(711.7)$ $464.00(260.71)$ 0.058 Clinical course and mortality:BPs on admission 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) $5(100)$ $41(82)$ 0.299 Dyspnea (%) $0(0)$ $6(12)$ 0.411 Killip class III/IV on admission (%) $1(20)$ $5(100)$ 0.494 Pneumonia (%) $1(20)$ $13(26)$ 0.769 Rhythm disturbances (%) $0(0)$ $4(8)$ 0.511 Hospital mortality (%) $4(80)$ $4(8)$ <0.0001 | CRP (mg/L) | 13.70 ((40.20)) | 20.35 ((27.30)) | 0.933 |
| Clinical course and mortality: BPs on admission 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) $5(100)$ $41(82)$ 0.299 Dyspnea (%) $0(0)$ $6(12)$ 0.411 Killip class III/IV on admission (%) $1(20)$ $5(100)$ 0.494 Pneumonia (%) $1(20)$ $13(26)$ 0.769 Rhythm disturbances (%) $0(0)$ $4(8)$ <0.0001 | BNP (pg/mL) | 974.65 (711.7) | 464.00 (260.71) | 0.058 |
| BPs on admission 123.00 ± 36.51 123.28 ± 23.94 0.981 HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) $5(100)$ $41(82)$ 0.299 Dyspnea (%) $0(0)$ $6(12)$ 0.411 Killip class III/IV on admission (%) $1(20)$ $5(100)$ 0.494 Pneumonia (%) $1(20)$ $13(26)$ 0.769 Rhythm disturbances (%) $0(0)$ $4(8)$ 0.511 Hospital mortality (%) $4(80)$ $4(8)$ <0.0001 | Clinical course and mortality: | | | |
| HR on admission 95.75 ± 22.46 68.38 ± 11.42 <0.0001 Retrosternal chest pain (%) $5(100)$ $41(82)$ 0.299 Dyspnea (%) $0(0)$ $6(12)$ 0.411 Killip class III/IV on admission (%) $1(20)$ $5(100)$ 0.494 Pneumonia (%) $1(20)$ $13(26)$ 0.769 Rhythm disturbances (%) $0(0)$ $4(8)$ 0.511 Hospital mortality (%) $4(80)$ $4(8)$ <0.0001 | BPs on admission | 123.00 ± 36.51 | 123.28 ± 23.94 | 0.981 |
| Retrosternal chest pain (%) 5 (100) 41 (82) 0.299 Dyspnea (%) 0 (0) 6 (12) 0.411 Killip class III/IV on admission (%) 1 (20) 5 (10) 0.494 Pneumonia (%) 1 (20) 13 (26) 0.769 Rhythm disturbances (%) 0 (0) 4 (8) 0.511 Hospital mortality (%) 4 (80) 4 (8) <0.0001 | HR on admission | 95.75 ± 22.46 | 68.38 ± 11.42 | < 0.0001 |
| Dyspnea (%) 0 (0) 6 (12) 0.411 Killip class III/IV on admission (%) 1 (20) 5 (10) 0.494 Pneumonia (%) 1 (20) 13 (26) 0.769 Rhythm disturbances (%) 0 (0) 4 (8) 0.511 Hospital mortality (%) 4 (80) 4 (8) <0.0001 | Retrosternal chest pain (%) | 5 (100) | 41 (82) | 0.299 |
| Killip class III / IV on admission (%) 1 (20) 5 (10) 0.494 Pneumonia (%) 1 (20) 13 (26) 0.769 Rhythm disturbances (%) 0 (0) 4 (8) 0.511 Hospital mortality (%) 4 (80) 4 (8) <0.0001 | Dyspnea (%) | 0(0) | 6 (12) | 0.411 |
| Pneumonia (%) 1 (20) 13 (26) 0.769 Rhythm disturbances (%) 0 (0) 4 (8) 0.511 Hospital mortality (%) 4 (80) 4 (8) <0.0001 | Killip class III/IV on admission (%) | 1 (20) | 5 (10) | 0.494 |
| Rhythm disturbances (%) $0(0)$ $4(8)$ 0.511 Hospital mortality (%) $4(80)$ $4(8)$ <0.0001 | Pneumonia (%) | 1 (20) | 13 (26) | 0.769 |
| Hospital mortality (%) $4(80)$ $4(8)$ <0.001 | Rhythm disturbances (%) | 0(0) | 4 (8) | 0.511 |
| | Hospital mortality (%) | 4 (80) | 4 (8) | < 0.0001 |

 Table 1. Results comparison of the two groups.

| | TS+CR Group n = 5 | TS Control Group $n = 50$ | <i>p</i> -Value |
|--------------------------------|----------------------|---------------------------|-----------------|
| Pharmacological treatment: | | | |
| Unfractionated heparin (%) | 1 (20) | 17 (34) | 0.524 |
| Enoxaparin (%) | 4 (80) | 28 (56) | 0.299 |
| Clopidogrel (%) | 3 (60) | 43 (86) | 0.134 |
| Aspirin (%) | 5 (100) | 49 (98) | 0.749 |
| Statin (%) | 5 (100) | 44 (88) | 0.412 |
| Beta blocker (%) | 5 (100) | 45 (90) | 0.458 |
| ACE inhibitor/AT-R blocker (%) | 4 (80) | 46 (92) | 0.374 |
| Diuretics (%) | 4 (80) | 25 (50) | 0.200 |
| Proton pump inhibitor (%) | 5 (100) | 45 (90) | 0.458 |
| Pressor amines (%) | 3 (60) | 8 (16) | 0.019 |

Table 1. Cont.

Data are presented as arithmetic means \pm standard deviations, medians ((interquartile interval)), and numbers (percentages). Abbreviations: ACE, angiotensin converting enzyme; AlAT, alanine aminotransferase; AspAT, aspartate aminotransferase; AT-R, angiotensin receptor; BNP, B-type natriuretic peptide; BPs, systolic blood pressure; COPD, chronic obstructive pulmonary disease; CHA2DS2-VASc, congestive heart failure, hypertension, age (>65 = 1 point; >75 = 2 points), diabetes, previous stroke/transient ischemic attack (2 points)-vascular disease; CK, creatine kinase; CRP, C-reactive protein; CR, cardiac rupture; LDL, low-density lipoprotein; GRACE, the Global Registry of Acute Coronary Events; HDL, high-density lipoprotein; HR, heart rate; eGFR MDRD, estimated glomerular filtration rate using modified diet renal disease; ECG, electrocardiogram; SD, standard deviation; TS, Takotsubo syndrome; TS+CR, Takotsubo syndrome with complications of cardiac rupture.

3.2. ECG—ST Segment Elevation

ST segment elevations were observed in all five patients in the TS+CR group on admission, and 66% in the control group. In all patients with CR, ST elevations were located in the V4, V5 and V6 leads, while in three patients, in leads from the lower wall as well. Compared to the control group, in patients with CR, ST elevation was significantly more often recorded in leads III, V4, V5, and V6 (Figure 1 and Table 2).



Figure 1. Comparison of ST segment elevations in the TS groups.

| Case | Ι | II | III | aVL | aVF | V1 | V2 | V3 | V4 | V 5 | V6 |
|-------------------------|-------|-------|-------|-----|-------|-------|-------|-------|-------|------------|-------|
| Case 1 | | | | | | | + | + | + | + | + |
| Case 2 | | + | + | | + | | + | + | + | + | + |
| Case 3 | + | | | + | | + | + | + | + | + | + |
| Case 4 | | + | + | | + | | | | + | + | + |
| Case 5 | | + | + | | + | | | + | + | + | + |
| TS+CR (%) | 20 | 60 | 60 | 20 | 60 | 20 | 60 | 80 | 100 | 100 | 100 |
| TS control group (%) | 28 | 26 | 12 | 20 | 22 | 24 | 50 | 52 | 40 | 32 | 32 |
| <i>p</i> -Value | 0.701 | 0.110 | 0.005 | _ | 0.062 | 0.841 | 0.669 | 0.231 | 0.010 | 0.002 | 0.002 |

Table 2. ST segment elevations in patients with Takotsubo syndrome and cardiac rupture.

Data are presented as percentages. Abbreviation: TS+CR, Takotsubo syndrome with complications of cardiac rupture.

3.3. Cardiac Rupture

In one patient, CR occurred on the first day of hospitalization, which was detected during coronarography with ventriculography. In two patients, CR occurred on the second day of hospitalization, and in the other two patients, CR occurred on the fifth day of hospitalization. In these four patients, CR was diagnosed during echocardiography—in two after cardiac arrest during resuscitation, and in two due to symptoms of cardiogenic shock. The left ventricular free wall rupture was noted in four patients, and in one case, it was the rupture of the ventricular septum with a left–right shunt. The patient whose CR was detected during coronarography was cardio-surgically treated and survived, and the remaining patients died (Table 3).

Table 3. Clinical characteristics and imaging of the five cases.

| Case | Age (Years) | Sex (F/M) | Symptoms at Admission | ECG at Admission | ECHO at Admission | LVEF ECHO | Coronarography | Ventriculography | Last ECHO | CR—Day of Hospitalization |
|--------|----------------|--------------|---|---|---|-----------|--|---|---------------------------------------|------------------------------|
| Case 1 | 74 | F | Retrosternal pain, cardiogenic shock | SR 58/min, elevation ST in leads V2–V6 | Akinesis of the apex with hyperkinesis of the other LV wall segments, tamponade | 55% | Mural atherosclerotic lesions in the coronary arteries | EF 56%Visible contrast leakage around the LV apex | EF—50% (discharge) | Day 1 |
| Case 2 | 79 | F | Retrosternal pain | SR 50/min, ST elevation with negative T waves in II, III, aVF, and V2–V6 | Akinesis of the apex and apical LV wall segments | 43% | No atherosclerotic lesions in the coronary arteries | Akinesis aneurysm of the LV apex, EF—40% | LV free wall rupture, tamponade | Day 2—Death |
| Case 3 | 84 | F | Restosternal pain, cardiogenic shock | SR 90/min, ST elevation in I, aVL, and V1–V6 | Akinesis of the apex and apical and central LV wall segments | 30% | Mural atherosclerotic lesions | Not performed | VSD with left-right shut | Day 2 Death on Day 5 |
| Case 4 | 88 | F | Restosternal pain | FA 71/min, ST elevation in II, III, aVF, V4–V6, and negative T in V4–V6 | A/dyskinesis of the apex and apical LV wall segments | 38% | 40%–50% RCA, mural lesions in others | EF—32% | LV free wall rupture, tamponade | Day 5—Death |
| Case 5 | 85 | F | Restosternal pain | FA 108/min, ST elevations in II, III, aVF, V3–V6, negative T in I, II, III, aVL, aVF, and V3–V6 | A/dyskinesis of the apex and apical LV wall segments, hypokinesis of central segment | 35% | 80% 1D, insignificant lesions in others | EF—35% | LV free wall rupture, tamponade | Day 5—Death |

Abbreviations: CR, cardiac rupture; D1, diagonal branch; ECG, electrocardiogram; ECHO, echocardiogram; EF, ejection fraction; FA, atrial fibrillation; F/M, female/male; LV, left ventricle; LVEF, left ventricular ejection fraction; RCA, right coronary artery; SR, sinus rhythm; VSD, ventricular septal defect.

In multivariate logistic regression, the factors that increase the risk of CR in TS are high GRACE scores, and the presence of ST segment elevation in lead III. Table 4 shows the results of our analyses.

| | | Univariate | | | Multivariate | |
|---------------------|------------|---------------|-----------------|------------|----------------|-----------------|
| Predictor | Odds Ratio | 95% CI | <i>p</i> -Value | Odds Ratio | 95% CI | <i>p-</i> Value |
| Age (years) | 1.229 | 1.035-1.459 | 0.0187 | | | |
| Emotional trigger | 2.912 | 0.443-19.130 | 0.266 | | | |
| BPs | 1.000 | 0.963-1.038 | 0.9807 | | | |
| Hypertension | 2.667 | 0.277-25.637 | 0.3956 | | | |
| HR | 0.964 | 0.911-1.020 | 0.202 | | | |
| EF < 40% | 0.987 | 0.901-1.082 | 0.778 | | | |
| Hemoglobin | 0.670 | 0.326-1.377 | 0.276 | | | |
| ST elevation in III | 29.333 | 2.793-308.040 | 0.004 | 25.500 | 2.278-4334.264 | 0.017 |
| ST elevation in V5 | 8.500 | 0.878-82.315 | 0.064 | | | |
| AspAT | 1.022 | 0.998 - 1.047 | 0.077 | | | |
| Glucose | 1.017 | 1.000 - 1.035 | 0.051 | | | |
| LDL | 0.984 | 0.984-1.016 | 0.323 | | | |
| GRACE points | 1.064 | 1.014-1.116 | 0.011 | 1.064 | 1.003-1.104 | 0.036 |

Table 4. Results of the univariate and multivariate logistic regression analyses—risk factors for cardiac rupture in Takotsubo syndrome.

Abbreviations: CI, confidence interval; BP, blood pressure; HR, heart rate; EF, ejection fraction; LDL, low-density lipoprotein; GRACE, the Global Registry of Acute Coronary Events.

3.4. Systematic Review

Table 5 shows all case descriptions on CR in TS found in the PubMed database.

Table 5. Reported cases of cardiac rupture in Takotsubo syndrome (n = 35).

| Author(s) and Year of Publication | Age (Years) | Sex (F/M) | Place of Perforation | Death (+) | Treatment |
|--------------------------------------|-------------|-----------|-------------------------|--------------|-----------------|
| Akashi et al. in 2004 [7] | 70 | F | Free wall LV | + | |
| Sakai et al. in 2005 [8] | 84 | F | VSD | + | |
| Ohara et al. in 2005 [9] | 79 | F | Free wall LV | + | |
| Ishida et al. in 2005 [10] | 67 | F | Free wall LV | _ | Cardiac surgery |
| Mafrici et al. in 2006 [11] | 87 | F | Free wall LV | + | |
| Yamada et al. in 2006 [12] | 71 | F | Free wall LV | + | |
| Shinozaki et al. in 2007 [13] | 90 | F | Free wall LV | + | |
| Sacha et al. in 2007 [14] | 81 | F | Free wall LV | + | |
| Izumi et al. in 2008 [15] | 73 | F | VSD | _ | Cardiac surgery |
| Ieva et al. in 2009 [16] | 65 | F | RV | + | 0, |
| Stöllberger et al. in 2009 [17] | 71 | F | Free wall LV | + | |
| Tsunoda et al. in 2010 [18] | 74 | F | Free wall LV | + | |
| Mariscalco et al. in 2010 [19] | 71 | F | Free wall LV | - | Cardiac surgery |
| Kurisu et al. in 2012 [20] | 81 | F | Free wall LV | + | |
| Jaguszewski et al. in 2012 [21] | 82 | F | Free wall LV | + | |
| Yoshida et al. in 2013 [22] | 78 | F | Free wall LV | - | Conservative |
| Kumar et al. in 2012 [23] | 62 | F | Free wall LV | + | |
| Y-Hassan et al. in 2014 [24] | 73 | М | Free wall LV | + | |
| Indorato et al. in 2015 [25] | 70 | F | Free wall LV | + | |
| Aikawa et al. in 2015 [26] | 81 | F | VSD | + | |
| Showkathali et al. in 2015 [27] | 86 | F | Free wall LV | + | |
| Miyake et al. in 2015 [28] | 73 | М | VSD | + | |
| Zalewska-Adamiec et al. in 2016 [29] | 74 | F | Free wall LV | - | Cardiac surgery |
| Pepe et al. in 2016 [30] | 84 | F | VSD | _ | Occluder |
| Sung et al. in 2017 [31] | 73 | F | RV + VSD | + | |
| Mitchell et al. in 2017 [32] | 82 | F | RV | + | |

| atment |
|-----------|
| c surgery |
| |
| ervative |
| c surgery |
| cluder |
| |
| cluder |
| |
| c surgery |
| |

Table 5. Cont.

Abbreviations: VSD, ventricular septal defect; RV, right ventricle; LV, left ventricle.

4. Discussion

Left ventricular wall rupture is undoubtedly the most serious mechanical complication of both myocardial infarction and Takotsubo syndrome. Due to the increasing tamponade, without rapid cardiac intervention, most patients die. The introduction of an effective treatment for the causal myocardial infarction with percutaneous coronary angioplasty has significantly reduced the incidence of cardiac rupture, which is now detected in only 2–4% of the patients with myocardial infarction [42]. Usually, cardiac rupture occurs in older patients with myocardial infarction who have been treated with conservative or delayed coronary angioplasty, and the rupture site is within the necrotic wall.

Left ventricular wall perforation in the course of Takotsubo syndrome is also usually fatal, but it occurs rarely, in approximately 1% of patients [5,43,44]. In our register, the percentage of CR during TS is slightly higher (1.89%). The pathophysiological mechanism of cardiac rupture in Takotsubo syndrome is not yet fully understood. Autopsy studies have thus far described the atrophy of myocyte striations and features of inflammation with foci of necrosis in the area of the ventricular wall rupture [8,14,22,39].

In 2011, Kumar et al. [5] conducted the first systematic review of all cases of CR in TS available in the MEDLINE database from 1950 to 2009, and collected 12 patients reported from 2004 to 2009. The group, as in our analysis, was made up of women themselves, aged 62–90 (average age = 76). Rupture of the ventricular septum was detected in two patients, perforation in the right ventricular septum in two women, and perforation in the left ventricular free wall in seven women. In the case of one patient, the site of perforation was not reported. Out of the 12 patients included in the review of Kumar et al., 10 patients (83%) died, including half of them in the first two days of hospitalization; the remaining patients died in the next eight days. Such high mortality rates obtained in the systematic review and in this study (80%) are comparable to the deaths of patients with cardiac rupture during myocardial infarction not treated with cardiac surgery [45].

Another review of Takotsubo syndrome complicated by cardiac rupture was performed by Dalia et al. [38]. They analyzed 20 cases from the MEDLINE database with a rupture of the left ventricular free wall. The majority of these patients were women (95%) with an average age of 74.9 years. Dalia et al. reported a mortality rate of 85%.

Currently, the PubMed database contains 35 case studies on CR in Takotsubo syndrome. Most patients were women, but there were also three men. The youngest patient was 57 years old, and the oldest was 92 years; 29 patients were aged over 70 years. The free wall of the left ventricle ruptured in 22 patients, the free wall of the right ventricle ruptured in three patients, and perforation in the ventricular septum was recorded in 10 cases. Out of 35 patients, 23 died; 17 patients with a rupture of the free wall of the left ventricle (77.3%), three women with a rupture of the right ventricle (100%), and three patients with a rupture of the interventricular septum (30%). A total of 12 patients survived, including five patients with left ventricular free wall rupture, of whom four patients were treated with cardiac surgery and one patient was treated with conservative treatment. In

addition, seven patients with ventricular septal perforation survived, six of whom were treated surgically and one was treated conservatively.

In this study, out of the five patients in the TS+CR group, four people (80%) died. Among them, CR occurred on the second and fifth days of hospitalization. One patient survived thanks to cardiac surgery. The data in the literature on the survival of patients with CR in TS show that the prognosis of patients with ventricular septal perforation is better. In published cases, the ruptured septum was supplied by cardiac surgery or closed by an occlude [30,37,39]. Izumi et al. [15] described the history of a 73-year-old patient with stress cardiomyopathy, who had a perforated ventricular septum on the first day of hospitalization. The patient survived, although she was operated on only on day 22 after the rupture of the ventricular septum. The prognosis is much worse in patients with the rupture of the free wall of the left or, less frequently, of the right ventricle. Out of 25 patients from the PubMed database, 20 people died, whereas the patients undergoing cardiac surgery survived.

In the TS+CR group, there were significantly higher values for glycemia. These patients did not suffer from diabetes and the values of HbA_{1C} were normal. Therefore, hyperglycemia should be explained by the high secretion of catecholamines.

The etiology of cardiac rupture in Takotsubo syndrome is undoubtedly multifactorial. According to Kumar et al., the factors conducive to left ventricular perforation are female gender, older age, higher arterial pressure, presence of ST elevation in the inferior wall leads, low left ventricular ejection fraction, and high peak left ventricular systolic fraction. Our analysis of patients with CR in TS compared to the control group undoubtedly shows that the factors that increase the risk of CR in TS are older age, a higher concentration of cardiac enzymes, higher GRACE scores, faster heart rate, and ST elevation in ECG, especially in leads V4–V6 and the inferior wall leads.

The analyzed series of five cases, as well as those quoted in the data in the literature, prove the importance of the monitoring and observation of patients with TS and risk factors for CR during the first few days of diagnosis of TS. Only a quick diagnosis of perforation, decompression of the subsequent tamponade, and urgent cardiac surgery offer these patients a chance to survive.

Limitations

The primary limitation of this study is the small number of patients—only five patients with a CR were studied, due to the rarity of this complication and the limitation of the Takotsubo syndrome register to the Podlaskie Voivodeship.

5. Conclusions and Clinical Implications

Cardiac rupture in Takotsubo syndrome is rare but is the most severe mechanical complication and is associated with a very high risk of death. Female gender, older age, a higher concentration of cardiac enzymes, a higher number of points in GRACE scale, a faster heart rate, and ST elevations in ECG, especially in the lower and anterior wall ventricular leads, are the main risk factors for left ventricular perforation. Only intensive monitoring in the acute phase of the disease allows for a quick diagnosis of CR, and urgent surgical intervention offers these patients a chance to survive.

Author Contributions: Conceptualization, M.Z.-A. and H.B.-G.; methodology, M.Z.-A.; software, M.Z.-A.; validation, M.Z.-A., H.B.-G. and S.D.; formal analysis, M.Z.-A.; investigation, M.Z.-A.; resources, M.Z.-A.; data curation, M.Z.-A.; writing—original draft preparation, M.Z.-A.; writing—review and editing, H.B.-G. and S.D.; visualization, M.Z.-A.; supervision, M.Z.-A.; project administration, M.Z.-A.; funding acquisition, H.B.-G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Bioethics Committee of the Medical University of Bialystok (code R-I-002/410/2019).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: The authors would like to express their thanks to Paweł Drozdowski and Jerzy Bychowski for providing the medical records of Takotsubo syndrome patients.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Sato, H.; Tateishi, H.; Uchida, T. Takotsubo-type cardiomyopathy due to multivessel spasm. In *Clinical Aspect of Myocardial Injury: From Ischemia to Heart Failure*; Kodama, K., Haze, K., Hon, M., Eds.; Kagakuhyouronsha: Tokyo, Japan, 1990; pp. 56–64.
- Ghadri, J.R.; Wittstein, I.S.; Prasad, A.; Sharkey, S.; Dote, K.; Akashi, Y.J.; Cammann, V.L.; Crea, F.; Galiuto, L.; Desmet, W.; et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. *Eur. Heart J.* 2018, 39, 2032–2046. [CrossRef]
- Ghadri, J.R.; Wittstein, I.S.; Prasad, A.; Sharkey, S.; Dote, K.; Akashi, Y.J.; Cammann, V.L.; Crea, F.; Galiuto, L.; Desmet, W.; et al. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. *Eur. Heart J.* 2018, *39*, 2047–2062. [CrossRef]
- 4. Nef, H.M.; Möllmann, H.; Elsässer, A. Tako-tsubo cardiomyopathy (apical ballooning). *Heart* 2007, *93*, 1309–1315. [CrossRef] [PubMed]
- 5. Kumar, S.; Kaushik, S.; Nautiyal, A.; Choudhary, S.K.; Kayastha, B.L.; Mostow, N.; Lazar, J.M. Cardiac rupture in takotsubo cardiomyopathy: A systematic review. *Clin. Cardiol.* **2011**, *34*, 672–676. [CrossRef] [PubMed]
- Bybee, K.A.; Kara, T.; Prasad, A.; Lerman, A.; Barsness, G.W.; Wright, R.S.; Rihal, C.S. Systematic review: Transient left ventricular apical ballooning: A syndrome that mimics ST-segment elevation myocardial infarction. *Ann. Intern. Med.* 2004, 141, 858–865. [CrossRef] [PubMed]
- Akashi, Y.J.; Tejima, T.; Sakurada, H.; Matsuda, H.; Suzuki, K.; Kawasaki, K.; Tsuchiya, K.; Hashimoto, N.; Musha, H.; Sakakibara, M.; et al. Left ventricular rupture associated with Takotsubo cardiomyopathy. *Mayo Clin. Proc.* 2004, *79*, 21–24. [CrossRef]
- 8. Sakai, K.; Ochiai, H.; Katayama, N.; Nakamura, K.; Arataki, K.; Kido, T.; Iwamoto, H.; Nakamura, S.; Nakanishi, T. Ventricular septal perforation in a patient with takotsubo cardiomyopathy. *Circ. J.* **2005**, *69*, 365–367. [CrossRef]
- 9. Ohara, Y.; Hiasa, Y.; Hosokawa, S.; Tomokane, T.; Yamaguchi, K.; Ogura, R.; Miyajima, H.; Ogata, T.; Yuba, K.; Suzuki, N.; et al. Left ventricular free wall rupture in transient left ventricular apical ballooning. *Circ. J.* **2005**, *69*, 621–623. [CrossRef]
- 10. Ishida, T.; Yasu, T.; Arao, K.; Kawakami, M.; Saito, M. Bedside diagnosis of cardiac rupture by contrast echocardiography. *Circulation* **2005**, *112*, e354–e355. [CrossRef] [PubMed]
- 11. Mafrici, A.; Proietti, R.; Fusco, R.; De Biase, A.; Klugmann, S. Left ventricular free wall rupture in a Caucasian female with takotsubo syndrome: A case report and a brief literature review. *J. Cardiovasc. Med.* **2006**, *7*, 880–883. [CrossRef] [PubMed]
- Yamada, R.; Watanabe, N.; Kume, T.; Kawamoto, T.; Okahashi, N.; Wada, N.; Koyama, Y.; Toyota, E.; Okura, H.; Yoshida, K. Left ventricular rupture associated with takotsubo-like left ventricular dysfunction (apical ballooning). *J. Echocardiogr.* 2006, *4*, 59–62. [CrossRef]
- 13. Shinozaki, K.; Tamura, A.; Abe, Y.; Yano, S.; Kadota, J. Left ventricular free wall rupture in takotsubo cardiomyopathy. *Int. J. Cardiol.* **2007**, *115*, e3–e4. [CrossRef] [PubMed]
- 14. Sacha, J.; Maselko, J.; Wester, A.; Szudrowicz, Z.; Pluta, W. Left ventricular apical rupture caused by takotsubo cardiomyopathy— Comprehensive pathological heart investigation. *Circ. J.* **2007**, *71*, 982–985. [CrossRef]
- 15. Izumi, K.; Tada, S.; Yamada, T. A case of Takotsubo cardiomyopathy complicated by ventricular septal perforation. *Circ. J.* **2008**, 72, 1540–1543. [CrossRef]
- 16. Ieva, R.; Correale, M.; Brunetti, N.D.; Di Biase, M. A "bad" case of Tako-Tsubo syndrome. *J. Thromb. Thrombolysis* **2009**, *28*, 248–251. [CrossRef] [PubMed]
- 17. Stöllberger, C.; Huber, J.O.; Enzelsberger, B.; Finsterer, J. Fatal outcome of epileptic seizure-induced takotsubo syndrome with left ventricular rupture. *Eur. J. Neurol.* **2009**, *16*, e116–e117. [CrossRef] [PubMed]
- Tsunoda, S.; Tando, S.; Doi, T.; Kitamura, Y.; Ogawa, M.; Tanabe, S.I.; Yamada, C.; Yasukawa, S.; Oda, Y. Left ventricular free wall rupture associated with a combination of acute myocardial infarction and stress-provoked cardiomyopathy: An autopsy case. *J. Cardiol. Cases* 2010, 2, e119–e122. [CrossRef] [PubMed]

- 19. Mariscalco, G.; Cattaneo, P.; Rossi, A.; Baravelli, M.; Piffaretti, G.; Scannapieco, A.; Nassiacos, D.; Sala, A. Tako-tsubo cardiomyopathy complicated by ventricular septal perforation and septal dissection. *Heart Vessels* **2010**, *25*, 73–75. [CrossRef]
- 20. Kurisu, S.; Inoue, I. Cardiac rupture in tako-tsubo cardiomyopathy with persistent ST-segment elevation. *Int. J. Cardiol.* 2012, 158, e5–e6. [CrossRef] [PubMed]
- Jaguszewski, M.; Fijalkowski, M.; Nowak, R.; Czapiewski, P.; Ghadri, J.R.; Templin, C.; Rynkiewicz, A. Ventricular rupture in Takotsubo cardiomyopathy. *Eur. Heart. J.* 2012, 33, 1027. [CrossRef] [PubMed]
- 22. Yoshida, S.; Miwa, K.; Matsubara, T.; Yasuda, T.; Inoue, M.; Teramoto, R.; Okada, H.; Kanaya, H.; Hayashi, K.; Konno, T.; et al. Stress-induced takotsubo cardiomyopathy complicated with wall rupture and thrombus formation. *Int. J. Cardiol.* **2012**, *161*, e18–e20. [CrossRef]
- 23. Kumar, S.; Kaushik, S.; Nautiyal, A.; Mostow, N.; Lazar, J.M. Pathology findings mimicking acute myocardial infarction in a case of Takotsubo cardiomyopathy complicated by cardiac rupture. *J. Cardiovasc. Med.* **2012**, *13*, 478–480. [CrossRef] [PubMed]
- 24. Y-Hassan, S. Cardiac rupture in a patient with Takotsubo syndrome triggered by acute myocardial infarction: Two messages. *Int. J. Cardiol.* **2014**, *177*, 162–165. [CrossRef] [PubMed]
- 25. Indorato, F.; Akashi, Y.J.; Rossitto, C.; Raffino, C.; Bartoloni, G. Takotsubo cardiomyopathy associated with rupture of the left ventricular apex: Assessment of histopathological features of a fatal case and literature review. *Forensic. Sci. Med. Pathol.* **2015**, *11*, 577–583. [CrossRef]
- 26. Aikawa, T.; Sakakibara, M.; Takahashi, M.; Asakawa, K.; Dannoura, Y.; Makino, T.; Koya, T.; Tsutsui, H. Critical takotsubo cardiomyopathy complicated by ventricular septal perforation. *Intern. Med.* **2015**, *54*, 37–41. [CrossRef]
- 27. Showkathali, R.; Dworakowski, R.; MacCarthy, P. Catastrophic ruptured Takotsubo cardiomyopathy. J. Cardiovasc. Med. 2015, 16, 644–645. [CrossRef]
- 28. Miyake, K.; Funatsu, T.; Kondoh, H.; Taniguchi, K. Rare Complication of Takotsubo Cardiomyopathy: Ventricular Septal Perforation with Septal Dissection. *J. Card. Surg.* **2016**, *31*, 150–153. [CrossRef] [PubMed]
- 29. Zalewska-Adamiec, M.; Bachórzewska-Gajewska, H.; Kożuch, M.; Frank, M.; Hirnle, T.; Dobrzycki, S. Cardiac rupture in takotsubo cardiomyopathy treated surgically. *Postepy. Kardiol. Interwencyjnej.* **2016**, *12*, 278–279. [CrossRef]
- 30. Pepe, M.; Paradies, V.; Bortone, A.; De Cillis, E.; Cafaro, A.; Acquaviva, T.; Masi, F.; Quagliara, D.; Favale, S. 'Broken-heart' syndrome: Ventricular septal perforation in a takotsubo cardiomyopathy. *Future Cardiol.* **2016**, *12*, 255–259. [CrossRef]
- Sung, J.M.; Hong, S.J.; Chung, I.H.; Lee, H.Y.; Lee, J.H.; Kim, H.J.; Byun, Y.S.; Kim, B.O.; Rhee, K.J. Rupture of Right Ventricular Free Wall Following Ventricular Septal Rupture in Takotsubo Cardiomyopathy with Right Ventricular Involvement. *Yonsei Med. J.* 2017, 58, 248–251. [CrossRef] [PubMed]
- 32. Mitchell, A.; Marquis, F. Can takotsubo cardiomyopathy be diagnosed by autopsy? Report of a presumed case presenting as cardiac rupture. *BMC Clin. Pathol.* **2017**, *17*, 4. [CrossRef]
- Kudaiberdiev, T.; Akhmedova, I.; Imanalieva, G.; Abdildaev, I.; Jooshev, K.; Ashimov, J.; Mirzabekov, A.; Gaybildaev, J. Surgical treatment of left ventricular wall rupture, regarded as a consequence of Takotsubo cardiomyopathy. SAGE Open. Med. Case Rep. 2017, 5, 2050313X16689210. [CrossRef] [PubMed]
- 34. Iskander, M.; Abugroun, A.; Shehata, K.; Iskander, F.; Iskander, A. Takotsubo Cardiomyopathy-Induced Cardiac Free Wall Rupture: A Case Report and Review of Literature. *Cardiol. Res.* **2018**, *9*, 244–249. [CrossRef]
- Narita, M.; Sakakura, K.; Ohashi, J.; Ibe, T.; Yamamoto, K.; Wada, H.; Momomura, S.I.; Fujita, H. Medically Treated Ventricular Septal Perforation Caused by Takotsubo Cardiomyopathy. *Int. Heart. J.* 2019, 60, 215–219. [CrossRef]
- Tsuji, M.; Isogai, T.; Okabe, Y.; Nishimura, Y.; Itagaki, S.; Enatsu, K.; Hisagi, M.; Nonaka, T.; Ninomiya, M.; Otsuka, T.; et al. Ventricular Septal Perforation: A Rare but Life-Threatening Complication Associated with Takotsubo Syndrome. *Intern. Med.* 2018, 57, 1605–1609. [CrossRef] [PubMed]
- De Manna, N.D.; Bellamoli, M.; Santoro, F.; Vinco, G.; Pilati, M.; Ribichini, F.; Faggian, G.; Milano, A.D. Midventricular Takotsubo cardiomyopathy complicated by a ventricular septal rupture: A surgical management. *J. Cardiovasc. Med.* 2019, 20, 837–840. [CrossRef]
- 38. Dalia, T.; Amr, B.S.; Agrawal, A.; Gautam, A.; Sethapati, V.R.; Kvapil, J. A Rare Case of Sudden Death in a Patient with Takotsubo Cardiomyopathy Secondary to Cardiac Rupture. *Case Rep. Cardiol.* **2019**, 2019, 5404365. [CrossRef] [PubMed]
- 39. Zhukova, N.S.; Merkulova, I.N.; Shakhnovich, R.M.; Merkulov, E.V.; Osiev, A.G.; Pevzner, D.V.; Sukhinina, T.S.; Staroverov, I.I. Endovascular closure of a ventricular septal defect from Takotsubo Syndrome. *Ter. Arkh.* **2019**, *91*, 115–123. [CrossRef] [PubMed]
- Webster, K.T.; Apridonidze, T.; Mopala, P.R.; Sherman, A.E.; Potakamuri, L.N.; Storms, D.R.; Kono, A.T.; Mohanty, B.D. Stress-Induced Cardiomyopathy Complicated by Dynamic Left Ventricular Outflow Obstruction, Cardiogenic Shock, and Ventricular Septal Rupture. *Can. J. Cardiol.* 2019, 35, 229.e7–229.e9. [CrossRef]
- 41. Al-Tkrit, A.; Mekaiel, A.; Aneeb, M.; Alawawdeh, F.; Mangla, A. Left Ventricular Free Wall Rupture in Broken-Heart Syndrome: A Fatal Complication. *Cureus* **2020**, *12*, e11316. [CrossRef]
- 42. Mathew, A.; Berry, E.; Tirou, M.; Kumar, P. Left ventricular rupture: A rare complication and an unusual presentation. *BMJ Case. Rep.* **2020**, *13*, e231867. [CrossRef] [PubMed]
- Kawai, S.; Suzuki, H.; Yamaguchi, H.; Tanaka, K.; Sawada, H.; Aizawa, T.; Watanabe, M.; Tamura, T.; Umawatari, K.; Kawata, M.; et al. Ampulla cardiomyopathy ('Takotsubo' cardiomyopathy)—Reversible left ventricular dysfunction: With ST segment elevation. *Jpn. Circ. J.* 2000, *64*, 156–159. [CrossRef] [PubMed]

- 44. Kurisu, S.; Sato, H.; Kawagoe, T.; Ishihara, M.; Shimatani, Y.; Nishioka, K.; Kono, Y.; Umemura, T.; Nakamura, S. Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: A novel cardiac syndrome mimicking acute myocardial infarction. *Am. Heart J.* **2002**, *143*, 448–455. [CrossRef] [PubMed]
- Ptaszynska-Kopczynska, K.; Sobolewska, D.; Kozuch, M.; Dobrzycki, S.; Sobkowicz, B.; Hirnle, T.; Musial, W.; Kaminski, K. Efficasy of invasive treatment and the occurrence of cardiac rupture in acute of ST-elevation myocardial infarction. *Kardiol. Pol.* 2011, 69, 795–800.